Spyre Therapeutics (SYRE) Enterprise Value (2016 - 2025)
Spyre Therapeutics (SYRE) has disclosed Enterprise Value for 11 consecutive years, with -$670.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 11.23% year-over-year to -$670.8 million, compared with a TTM value of -$486.2 million through Sep 2025, down 17.85%, and an annual FY2025 reading of -$670.8 million, down 11.23% over the prior year.
- Enterprise Value was -$670.8 million for Q4 2025 at Spyre Therapeutics, down from -$486.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$38.5 million in Q1 2023 and bottomed at -$670.8 million in Q4 2025.
- Average Enterprise Value over 5 years is -$286.7 million, with a median of -$219.5 million recorded in 2023.
- The sharpest move saw Enterprise Value skyrocketed 47.32% in 2022, then tumbled 1159.53% in 2024.
- Year by year, Enterprise Value stood at -$93.1 million in 2021, then surged by 40.18% to -$55.7 million in 2022, then plummeted by 508.99% to -$339.3 million in 2023, then crashed by 77.76% to -$603.1 million in 2024, then decreased by 11.23% to -$670.8 million in 2025.
- Business Quant data shows Enterprise Value for SYRE at -$670.8 million in Q4 2025, -$486.2 million in Q3 2025, and -$524.9 million in Q2 2025.